HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
23 hedge funds and large institutions have $7.34M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 12 closing their positions.
43% more capital invested
Capital invested by funds: $5.13M → $7.34M (+$2.21M)
18% less funds holding
Funds holding: 28 → 23 (-5)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
+$1.69M |
| 2 |
Squarepoint
New York
|
+$124K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$110K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$51.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$802K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$171K |
| 3 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$132K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$131K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$63K |
HTGM Hedge Fund Activity: Q4 2020 in Review
23 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2020, worth a combined $7.34M — up 43% from $5.13M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HTGM and 7 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Cowen Prime Advisors, adding an estimated $1.69M. The largest seller was Perkins Capital Management, exiting entirely with an estimated $802K sold.
- 23 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2020, down from 28 in Q3 2020.
- Funds reported $7.34M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2020, up 43% quarter-over-quarter.
- 7 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2020 and 12 closed out, a net change of -5 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2020 was Cowen Prime Advisors, an estimated $1.69M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2020 was Perkins Capital Management, an estimated $802K sold.
Based on aggregated 13F filings for Q4 2020.